Launching X–Labs for Breakthrough Science Act
- Bill Number
- H.R. 6572
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-12-10: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2026-03-09T12:25:43Z
AI-Generated Summary
Purpose of the Legislation
The "Launching X-Labs for Breakthrough Science Act" (H.R. 6572) aims to create a new program within the National Institutes of Health (NIH) called the "X-Labs Initiative." This program provides long-term funding to innovative research institutions to conduct high-risk, high-reward biomedical research that could lead to major advances in health and science. It focuses on supporting institutions that might not succeed under traditional NIH funding processes, while helping them build or expand research facilities.
Key Provisions
- Program Establishment: Adds a new section (404P) to the Public Health Service Act, directing the NIH Director to run the X-Labs Initiative. Awards are made competitively to "eligible entities" (explained below) either directly by NIH or through its institutes and centers.
- Purposes:
- To spark and enable breakthrough biomedical research (defined as research with potential for field-defining advances in knowledge, methods, or technologies that improve human health).
- To help institutions acquire "R&D plant" (fixed assets like labs, equipment, or facilities needed for research).
- Award Categories and Funding:
- XL01: For basic science research institutions focused on foundational discoveries (broad knowledge without specific applications in mind). Provides stable, long-term funding with few changes allowed to the budget.
- XL02: For institutions developing new scientific resources, like datasets or tools, with clear goals set at the start.
- XL03: For nonprofit organizations that pass funds ("regrants") to research teams, early projects, or collaborations with breakthrough potential. These regrants target groups unlikely to get traditional NIH support and must occur in the U.S. Recipients must use innovative ways to select and evaluate projects and publicly report their methods within one year.
- XL04: For planning or forming new institutions that could later qualify for other categories.
- Funding amounts: $5–50 million per year for 7 years for XL01–XL03 (renewable once for another 7 years after review); $1–5 million per year for 1–3 years for XL04 (no renewals).
- Awards use a new "XL-series" code across all NIH institutes.
- Eligibility and Rules:
- Eligible entities include nonprofits, universities, for-profit companies with nonprofit research arms, individuals planning nonprofits, or other groups approved by NIH.
- During the award period (for XL01–XL03), recipients cannot apply for or receive other federal research grants (except training grants).
- NIH can end awards early if goals aren't met, eligibility is lost, or terms are violated, then reallocate funds.
- Administration: NIH Director oversees the program, with input from institutes. Allows use of "other transactions authorities" (flexible funding methods outside standard grant rules).
- Reporting: NIH must report to Congress initially (within 1 year of enactment, then annually for 2 years) on setup, applications, and awards. Every 5 years after the first award, evaluate scientific impact, effectiveness, and ways to improve.
- Funding Authorization: Allows appropriations as needed for fiscal years 2026–2031.
Significant Changes to Existing Law
This bill amends the Public Health Service Act by adding a dedicated section for institutional awards focused on breakthrough research. It introduces a novel funding structure with the XL-series codes, emphasizing long-term, flexible support over short-term project grants. Unlike traditional NIH grants, it prohibits recipients from seeking other federal research funding during the award period, reduces administrative burdens, and prioritizes high-risk research. It also enables regrants through intermediaries and uses alternative contracting powers to speed up processes.
Potential Impacts
- Government Agencies: NIH will need to develop new application and review processes, potentially shifting resources toward innovative, domestic research. This could increase administrative workload initially but reduce it long-term by stabilizing funding for select institutions. Other federal agencies' research grants may see less competition from X-Labs recipients.
- Citizens: Could accelerate medical and scientific breakthroughs, leading to better health outcomes (e.g., new treatments or tools). Benefits U.S.-based researchers and the public through faster innovation, though funding is limited to specific institutions.
- International Relations: Emphasizes U.S.-based research (regrants must be domestic), potentially strengthening U.S. leadership in biomedical science but limiting global collaborations during award periods.
Main Stakeholders Affected
- NIH and Its Components: Directly responsible for administering awards, reporting, and evaluations; all 27 institutes and centers can participate.
- Research Institutions and Researchers: Eligible entities (nonprofits, universities, focused research organizations—time-limited groups targeting specific goals—and individuals starting new ones) gain access to substantial, stable funding for high-ambition projects.
- Congress: Receives regular reports and evaluations, influencing future funding and oversight.
- Broader Research Community: Early-stage teams and innovative projects benefit indirectly through regrants, especially those overlooked by standard funding.
Notable Legal, Constitutional, or Political Implications
- Legal: Relies on "other transactions authorities" (special flexible agreements under existing NIH powers), allowing quicker awards without full federal grant regulations. This could streamline funding but raises questions about oversight and accountability for large sums. Early termination and fund reallocation provide NIH strong enforcement tools.
- Constitutional: No direct challenges; aligns with Congress's spending power to promote general welfare through health research.
- Political: Introduced bipartisanship (by Reps. Harder (D) and Obernolte (R)), signaling broad support for innovation. The program's cap on renewals ensures turnover, preventing entrenchment, while congressional reporting promotes transparency without mandating specific outcomes.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Recent Actions
- 2025-12-10: Referred to the House Committee on Energy and Commerce.
- 2025-12-10: Introduced in House
- 2025-12-10: Introduced in House
Bill Versions
- Launching X–Labs for Breakthrough Science Act — issued 2025-12-10 — PDF (14 pages)